SEC Form 4 · accession 0001171843-18-003056
ARGOS THERAPEUTICS INC · ARGS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles A. Nicolette
Officer — CSO and Vice President of R&D
Period of report
Apr 25, 2018
Accepted (ET)
Apr 25, 2018 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001105533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 25, 2018 | D | 27,150 | $0.00 | D | 20,056 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares forfeited upon the delisting of the Company's common stock from The Nasdaq Capital Market.